the aid library

LIST OPTIONS

Filter

7896

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (820)

View PDF (2573)

Disabilities Among Refugees and Conflict-Affected Populations

Women's Refugee Commission (2008) C1

Resource Kit for Field workers

Download (265)

View PDF (268)

Anxiety disorders
recommended

National Institute for Health and Care Excellence (NICE) (2014) C2

Download (279)

View PDF (315)

Eating disorders: recognition and treatment

National Institute for Health and Care Excellence (NICE) (2017) C2

NICE guideline Published: 23 May 2017

Download (168)

View PDF (139)

List of key WHO-recommended maternal and newborn health commodities

World Health Organisation (WHO) (2024) C_WHO

This document provides a list of key WHO-recommended maternal and newborn health commodities and aims to accelerate progress towards the SDGs. It consolidates the key and enabling commodities from existing WHO guidelines on maternal and newborn health.

Download (212)

View PDF (238)

Guidelines for clinical placement in hospice and palliative care in Africa

Global Partners in Care; African Palliative Care Association (2014) CC

Download (587)

View PDF (1303)

South Sudan Situation Supplementary Appeal January - December 2017

UN High Commissioner for Refugees (2017) C1

Download (452)

View PDF (614)

Maternal and Child Health in Namibia

World Health Organization (WHO) (2009) C_WHO

2nd Edition

Download (250)

View PDF (192)

Including HIV in public and private sector insurance policies and products

International Labour Organization International Labour Organization (2020) C2

Accessed: 30.01.2020

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (152)

View PDF (200)

Indoor air quality at home

National Institute for Health and Care Excellence (NICE) (2020) C2

This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.

Download (3830)

View PDF (3265)

Standard Treatment Guidelines. Nigeria

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2008) C_WHO

Download (2160)

View PDF (1542)

Clinic Supervisor Manual

Management Sciences for Health; USAID (2006) C1

This Clinic Supervisor’s Manual is helpful for focusing managers on the key elements of integrated primary health care as they simultaneously integrate new interventions for HIV/AIDS, tuberculosis, and malaria. This tool contains 12 sections. Section 1 explains how to use the manual. Section 2 hel... more

Download (162)

View PDF (184)

Ending Aids - Progress towards the 90-90-90 targets

UNAIDS (2017) C2

Global AIDS Update 2017

Download (284)

View PDF (358)

World Drug Report 2022 Booklet 4 Drug market trends of Cocaine, Amphetamine-type stimulants and New Psychoactive Substances

United Nations Office on Drug and Crime UNODC (2022) C1

Constituting the fourth part of the World Drug Report 2022, this booklet focuses on the market dynamics of various stimulants – cocaine, amphetamines and “ecstasy” – and of NPS. The first chapter contains an analysis of the global market for cocaine, starting with a review of cocaine supply... more

Download (72)

View PDF (70)

Ghana - Country Cooperation Strategy 2024 - 2028

World Health Organization WHO (2025) C_WHO

The development of the Country Cooperation Strategy (CCS) was based on a consultative and participatory process with strong commitment and support from the Ministry of Health of Ghana. The CCS draws on lessons from the implementation of the first, and second generation CCSs, the country focus strate... more

Download (165)

View PDF (194)

Using TRIPS flexibilities to improve access to HIV treatment

UNAIDS (Joint United Nations Programme on HIVAIDS); World Health Organization; UNDP (2019) C2

Policy Brief Accessed: 20.11.2019

Download (34)

View PDF (24)

Plan of Action for Malaria Elimination 2021-2025

Pan American Health Organization (PAHO) (2022) C_WHO

The Plan of Action for Malaria Elimination 2021-2025 has been developed in consultation with countries and regional partners as a framework of reference to guide the efforts of countries and the contributions of donors and partners towards elimination of the disease in the Americas. The Plan subscri... more

Download (840)

View PDF (1180)

Zambia Demographic and Health Survey 2001-2002

Central Statistical Office Lusaka; Ministry of Health Zambia; Tropical Diseases Research Centre, Zambia, DHS; et al. (2003) C1

Download (608)

View PDF (1949)

Crisis and Emergency Risk Communication Quick Guide

Centers for Disease Control and Prevention (2008) C_CDC

Anxiety disorders recommended

Anxiety disorders
recommended